Yonsei Med J.  2019 Feb;60(2):208-215. 10.3349/ymj.2019.60.2.208.

Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea

Affiliations
  • 1Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea. helenmed@snu.ac.kr
  • 2Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
  • 3Regional Pharmacovigilance Center, Chungbuk National University Hospital, Cheongju, Korea.
  • 4Department of Internal Medicine, Kyung-Hee University Hospital, Seoul, Korea.
  • 5Regional Pharmacovigilance Center, Seoul National University Hospital, Seoul, Korea.
  • 6Drug Safety Monitoring Center, Seoul National University Hospital, Seoul, Korea.
  • 7Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.
  • 8Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
  • 9College of Pharmacy, Seoul National University, Seoul, Korea.
  • 10Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

PURPOSE
Despite morbidities and fatalities, nationwide epidemiologic data for severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), are not widely available. We aimed to investigate SCAR epidemiology over the last two decades in Korea.
MATERIALS AND METHODS
We analyzed individual case safety reports (ICSRs) of SCARs in the Korea Adverse Event Reporting System from 1988 to 2013. Administered drugs, demographic profiles, and causality assessment according to the World Health Organization-Uppsala Monitoring Center system were analyzed.
RESULTS
A total of 755 SCAR cases (508 SJS/TEN, 247 DRESS) were reported. The number of SCAR ICSRs has been increasing with increasing ICSRs for overall adverse drug events. Since 2010, the number of SCAR ICSRs has increased up to 100 cases/year. Allopurinol was the most common causative drug (SJS/TEN: 10.2%; DRESS: 11.3%; SCAR ICSRs: 10.6%), followed by carbamazepine (SJS/TEN: 8.7%; DRESS: 9.7%; SCAR ICSRs: 8.6%). Regarding drug groups, antiepileptics (19.5%) and antibiotics for systemic use (12.7%) were common causative drug groups. Twenty SCAR-related deaths were recorded. Antibacterials were the most common causes of deaths (8 cases), followed by antiepileptics (5 cases). The potential risk of SCARs was not specified in the drug information leaflet for 40.2% of drugs causing SJS/TEN and 82.5% causing DRESS syndrome in Korea.
CONCLUSION
The number of SCAR ICSRs has increased rapidly with recent active pharmacovigilance programs in Korea. Allopurinol and antiepileptics are the most common individual and categorical causative agents, respectively.

Keyword

Pharmacovigilance; Stevens-Johnson syndrome; toxic epidermal necrolysis; drug hypersensitivity syndrome

MeSH Terms

Allopurinol
Anti-Bacterial Agents
Anticonvulsants
Carbamazepine
Cause of Death
Cicatrix
Drug Hypersensitivity Syndrome
Drug-Related Side Effects and Adverse Reactions
Epidemiology
Global Health
Korea*
Pharmacovigilance
Stevens-Johnson Syndrome
Allopurinol
Anti-Bacterial Agents
Anticonvulsants
Carbamazepine

Figure

  • Fig. 1 Scheme of the selection process for ICSRs of SCARs in the KIDS-KD. ICSRs, individual case safety reports; SCARs, severe cutaneous adverse reactions; KIDS-KD, Korea Institute of Drug Safety and Risk Management-Korea Adverse Event Reporting System database; ADE, adverse drug event; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS syndrome, drug reaction with eosinophilia and systemic symptoms syndrome; DHS, drug hypersensitivity syndrome; WHO-ART, World Health Organization Adverse Reactions Terminology.

  • Fig. 2 Trends in annual numbers of ICSRs of SCARs in KAERS. ICSRs, individual case safety reports; SCARS, severe cutaneous adverse reactions; KAERS, Korea Adverse Event Reporting System; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS syndrome, drug reaction with eosinophilia and systemic symptoms syndrome.

  • Fig. 3 Proportion of causative drugs for SCARs categorized by the main therapeutic group (second level) per ATC classification. (A) Total, (B) SJS/TEN, (C) DRESS syndrome. SCARs, severe cutaneous adverse reactions; ATC, anatomical therapeutic chemical; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS syndrome, drug reaction with eosinophilia and systemic symptom syndrome. ATC code: B01 (antithrombotic agents), H02 (corticosteroids for systemic use), J01 (antibacterials for systemic use), J04 (antimycobacterials), L01 (antineoplastic agents), M01 (anti-inflammatory and antirheumatic products), M04 (anti-gout preparations), N02 (analgesics), N03 (antiepileptics), S01 (ophthalmologicals), and undetermined (cases in which two or more drugs were simultaneously reported as a causative agent so that the culprit drug could not be identified).


Cited by  3 articles

Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity
Wan Yin Winnie Yeung, Hae Sim Park
Yonsei Med J. 2020;61(1):4-14.    doi: 10.3349/ymj.2020.61.1.4.

Drug hypersensitivity reactions in Asia: regional issues and challenges
Bernard Yu-Hor Thong, Michaela Lucas, Hye-Ryun Kang, Yoon-Seok Chang, Philip Hei Li, Min Moon Tang, James Yun, Jie Shen Fok, Byung-Keun Kim, Mizuho Nagao, Iris Rengganis, Yi-Giien Tsai, Wen-Hung Chung, Masao Yamaguchi, Ticha Rerkpattanapipat, Wasu Kamchaisatian, Ting Fan Leung, Ho Joo Yoon, Luo Zhang, Amir Hamzah Abdul Latiff, Takao Fujisawa, Francis Thien, Mariana C. Castells, Pascal Demoly, Jiu-Yao Wang, Ruby Pawankar
Asia Pac Allergy. 2020;10(1):e8.    doi: 10.5415/apallergy.2020.10.e8.

Drug hypersensitivity reactions in Asia: regional issues and challenges
Bernard Yu-Hor Thong, Michaela Lucas, Hye-Ryun Kang, Yoon-Seok Chang, Philip Hei Li, Min Moon Tang, James Yun, Jie Shen Fok, Byung-Keun Kim, Mizuho Nagao, Iris Rengganis, Yi-Giien Tsai, Wen-Hung Chung, Masao Yamaguchi, Ticha Rerkpattanapipat, Wasu Kamchaisatian, Ting Fan Leung, Ho Joo Yoon, Luo Zhang, Amir Hamzah Abdul Latiff, Takao Fujisawa, Francis Thien, Mariana C. Castells, Pascal Demoly, Jiu-Yao Wang, Ruby Pawankar
Asia Pac Allergy. 2020;10(1):.    doi: 10.5415/apallergy.2020.10.e8.


Reference

1. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972; 498:1–25. PMID: 4625548.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200–1205. PMID: 9555760.
Article
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117–171. PMID: 25530442.
4. Swanson L, Colven RM. Approach to the patient with a suspected cutaneous adverse drug reaction. Med Clin North Am. 2015; 99:1337–1348. PMID: 26476256.
Article
5. Yang MS, Kang MG, Jung JW, Song WJ, Kang HR, Cho SH, et al. Clinical features and prognostic factors in severe cutaneous drug reactions. Int Arch Allergy Immunol. 2013; 162:346–354. PMID: 24193402.
Article
6. Kim SH, Lee KW, Song WJ, Kim SH, Jee YK, Lee SM, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 2011; 97:190–197. PMID: 21917426.
Article
7. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011; 21:303–307. PMID: 21301380.
Article
8. Kim MY, Yang MS, Kang HR, Cho SH, Min KU. Analysis of drugs causing severe cutaneous adverse reactions, based on the Korean Database of spontaneously reported adverse drug reactions. Korean J Med. 2014; 86:710–721.
Article
9. Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, et al. Incidence of Stevens-Johnson Syndrome and toxic epidermal necrolysis: a nationwide population-based study using National Health Insurance Database in Korea. PLoS One. 2016; 11:e0165933. PMID: 27835661.
Article
10. Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, et al. HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS/TEN according to culprit drugs. Yonsei Med J. 2016; 57:118–126. PMID: 26632391.
Article
11. Jung JW, Kim JY, Park IW, Choi BW, Kang HR. Genetic markers of severe cutaneous adverse reactions. Korean J Intern Med. 2018; 33:867–875. PMID: 29921043.
Article
12. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005; 102:4134–4139. PMID: 15743917.
13. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 2005; 65:437–447. PMID: 15853898.
Article
14. Jung JW, Kim DK, Park HW, Oh KH, Joo KW, Kim YS, et al. An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. Genet Med. 2015; 17:807–814. PMID: 25634024.
Article
15. Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 2015; 351:h4848. PMID: 26399967.
Article
16. Niihara H, Kaneko S, Ito T, Sugamori T, Takahashi N, Kohno K, et al. HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. J Dermatol Sci. 2013; 71:150–152. PMID: 23669020.
Article
17. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008; 18:99–107. PMID: 18192896.
Article
18. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011; 364:1126–1133. PMID: 21428768.
Article
19. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006; 16:297–306. PMID: 16538176.
Article
20. Lee KW, Jeon H, Park JY. HLA-B*15 diversity in the Korean population. Tissue Antigens. 2000; 56:428–435. PMID: 11144290.
Article
21. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008; 128:35–44. PMID: 17805350.
Article
22. Shu C, Shu D, Tie D, Yu M, Zhang R, Wang T, et al. Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01. Int J Dermatol. 2015; 54:1242–1245. PMID: 25970075.
23. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991; 127:839–842. PMID: 2036029.
24. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013; 133:1197–1204. PMID: 23389396.
Article
25. Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011; 32:237–245. PMID: 21228709.
Article
26. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009; 145:67–72. PMID: 19153346.
Article
27. Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008; 22:1044–1049. PMID: 18627428.
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr